Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.
OBJECTIVE To evaluate the cost utility of interferon beta-1b in secondary progressive multiple sclerosis. DESIGN Population based cost utility model (healthcare perspective). Data on use of health services were obtained from case records and routine morbidity data and utility values from a EuroQol survey. Local and published costs were used. Effectiveness was modelled using data on relative r...
متن کاملT(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
Recently, the clinical efficacy of interferon beta-1b (IFNbeta-1b) was demonstrated for secondary progressive (SP) multiple sclerosis in a European multicentre study. We evaluated the effect of IFNbeta-1b treatment on the rate of development of hypointense T(1) MRI lesions, a putative marker of axonal damage. Unenhanced T(1)-weighted images were obtained in a subgroup of 95 multiple sclerosis p...
متن کاملBeta‐interferon exposure and onset of secondary progressive multiple sclerosis
BACKGROUND AND PURPOSE Beta-interferons (IFNβ) are the most widely prescribed drugs for patients with multiple sclerosis (MS). However, whether or not treatment with IFNβ can delay secondary progressive MS (SPMS) onset remains unknown. Our aim was to examine the association between IFNβ exposure and SPMS onset in patients with relapsing-remitting MS (RRMS). METHODS A retrospective cohort stud...
متن کاملThe effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis
The recently completed European trial of interferon betahad a greater reduction of cerebral volume in the placebo group (mean reduction at month 36: placebo 5.1%, IFNβ1b (IFNβ-1b) in patients with secondary progressive 1b 1.8%, P < 0.05) whereas those with Gd-enhancing multiple sclerosis (SP multiple sclerosis) has given an lesions showed a trend to greater reduction of cerebral opportunity to ...
متن کاملApplication of Interferon Beta-1b in Multiple Sclerosis
Recombinant interferon beta-1b (IFNβ-1b) was the first approved disease-modifying therapy for patients with multiple sclerosis (MS) by the world regulatory agencies for medical drugs and devices. IFNβ-1b significantly decreases the inflammatory component of MS but still has doubtable effect on the neurodegenerative component. This article appraises the beneficial effects of IFNβ-1b on clinical ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1999
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.319.7224.1529